
HUTCHMED presents promising preclinical data for HMPL-A830, a novel cancer drug targeting EGFR and KRAS mutations.
HUTCHMED announced preclinical results for HMPL-A830, a new drug candidate combining an EGFR antibody with a potent KRAS inhibitor, designed to overcome resistance and toxicity in cancer treatment. The drug showed strong activity against multiple KRA...



